Kestra Advisory Services’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Kestra Advisory Services’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-77	Closed	-$28.7K	–	2872
2024 Q4	$28.7K	Buy	+77	New	+$23.1K	﹤0.01%	2630
2024 Q3	–	Sell	-77	Closed	-$11.5K	–	2697
2024 Q2	$11.5K	Buy	77 +12	+18%	+$2.17K	﹤0.01%	2601
2024 Q1	$13.7K	Buy	+65	New	+$16.1K	﹤0.01%	2440

Other funds holding IRLA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Kestra Advisory Services's IRLA Position: Q1 2025 in Review

Kestra Advisory Services sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q1 2025, closing a stake of 77 shares — an estimated $28.7K sold.

Kestra Advisory Services first reported a position in IRLA in Q1 2024 and held it in 3 quarters. The position peaked at $28.7K in Q4 2024. 32 funds tracked by Wall St. Rank hold IRLA as of Q1 2025.

Kestra Advisory Services reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Kestra Advisory Services sold 77 IRulya Therapeutics Inc. Common Stock shares in Q1 2025, an estimated $28.7K.
Kestra Advisory Services first reported a position in IRulya Therapeutics Inc. Common Stock in Q1 2024 and held it in 3 quarters.
Kestra Advisory Services's IRulya Therapeutics Inc. Common Stock position peaked at $28.7K in Q4 2024.
32 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q1 2025.

Based on Kestra Advisory Services's 13F filing for Q1 2025, filed 14 May 2025.